VRTX · Vertex Pharmaceuticals Inc / Ma · Earnings Call Transcripts & Audio
$522.81
-3.92 (-0.74%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$133.37B
Shares
253.46M
Volume · Sep 30
1.15M
Avg daily vol (3M)
1.23M
Vertex Pharmaceuticals Inc Earnings Call Transcripts
Quarterly earnings calls for Vertex Pharmaceuticals Inc (VRTX), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲17.7%
$2.33B
$930.50M
'22 Q3
22-10-27
▲11.1%
$2.30B
$818.90M
'22 Q4
23-02-07
▲13.2%
$2.37B
$699.80M
'23 Q1
23-05-01
▲13.5%
$2.49B
$915.70M
'23 Q2
23-08-01
▲6.4%
$2.48B
$1.04B
'23 Q3
23-11-06
▲9.3%
$2.52B
$968.80M
'23 Q4
24-02-05
▲13.3%
$2.69B
$1.10B
'24 Q1
24-05-06
▲6.1%
$2.65B
−$3.59B
'24 Q2
24-08-01
▲11.6%
$2.77B
$1.05B
'24 Q3
24-11-04
▲15.7%
$2.91B
$913.00M
'24 Q4
25-02-10
▲3%
$2.77B
$646.30M
'25 Q1
25-05-05
▲12.1%
$2.96B
$1.03B
'25 Q2
25-08-04
▲11%
$3.08B
$1.08B
'25 Q3
25-11-03
▲9.5%
$3.19B
$1.19B
'25 Q4
26-02-12
▲7.8%
$2.99B
$1.03B
'26 Q1
26-05-04
LATEST
▲12.5%
$3.33B
$1.10B
'26 Q2
26-08-03
Conference
Investor event
2026-09-09
Vertex Pharmaceuticals Inc (VRTX) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-03
Vertex Pharmaceuticals Inc (VRTX) Q2 2026 Earnings Call Transcript
Confident tone
Cystic Fibrosis Franchise
DM1 Program
Regulatory Milestones
Revenue
$3.33B
▲ 12.5% YoY Diluted EPS
$4.31
▲ 8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-07-06
Vertex Pharmaceuticals Inc (VRTX) July 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-10
Vertex Pharmaceuticals Inc (VRTX) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-29
Vertex Pharmaceuticals Inc (VRTX) May 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-04
Vertex Pharmaceuticals Inc (VRTX) Q1 2026 Earnings Call Transcript
Confident tone
Renal franchise / POVI (povetacicept)
Cystic Fibrosis franchise (Trikafta/Aliftrek)
Inaxaplin AMKD program
Revenue
$2.99B
▲ 7.8% YoY Diluted EPS
$4.02
▲ 61.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-11
Vertex Pharmaceuticals Inc (VRTX) March 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-12
Vertex Pharmaceuticals Inc (VRTX) Q4 2025 Earnings Call Transcript
Confident tone
Renal franchise and Povetacicept (POVI)
Clinical trial readouts and DSMB / Rainier study
Financial guidance and 2026 outlook
Revenue
$3.19B*
▲ 9.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-03
Vertex Pharmaceuticals Inc (VRTX) Q3 2025 Earnings Call Transcript
Confident tone
Cystic Fibrosis Franchise and ALYFTREK Uptake
Pain Portfolio (JOURNAVX in Acute and Neuropathic Pain)
Renal Pipeline (Povetacicept, Inaxaplin, VX-407)
Revenue
$3.08B
▲ 11% YoY Diluted EPS
$4.20
▲ 4.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-04
Vertex Pharmaceuticals Inc (VRTX) Q2 2025 Earnings Call Transcript
Confident tone
JOURNAVX (acute pain) launch and access
CF franchise and ALYFTREK launch
CASGEVY cell therapy momentum
Revenue
$2.96B
▲ 12.1% YoY Diluted EPS
$3.99
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-05
Vertex Pharmaceuticals Inc (VRTX) Q1 2025 Earnings Call Transcript
Revenue
$2.77B
▲ 3% YoY Diluted EPS
$2.49
▼ 40.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-10
Vertex Pharmaceuticals Inc (VRTX) Q4 2024 Earnings Call Transcript
Confident tone
JOURNAVX (suzetrigine) launch in acute pain
Cystic Fibrosis franchise performance and ALYFTREK launch
CASGEVY launch in sickle cell disease and beta thalassemia
Revenue
$2.91B*
▲ 15.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-04
Vertex Pharmaceuticals Inc (VRTX) Q3 2024 Earnings Call Transcript
Confident tone
Suzetrigine (VX-548) in acute pain and access
CASGEVY launch in sickle cell disease and beta thalassemia
Povetacicept in IgA nephropathy and broader autoimmune
Revenue
$2.77B
▲ 11.6% YoY Diluted EPS
$4.01
▲ 1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Vertex Pharmaceuticals Inc (VRTX) Q2 2024 Earnings Call Transcript
Confident tone
Suzetrigine acute pain launch
Cystic Fibrosis (Vanzacaftor Triple launch)
CASGEVI launch (sickle cell / beta-thalassemia)
Revenue
$2.65B
▲ 6.1% YoY Diluted EPS
$-13.92
▼ 495.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-06
Vertex Pharmaceuticals Inc (VRTX) Q1 2024 Earnings Call Transcript
Confident tone
Suzetrigine acute pain NDA and launch readiness
CASGEVY launch in sickle cell disease and beta thalassemia
Alpine Immune Sciences acquisition and povetacicept
Revenue
$2.69B
▲ 13.3% YoY Diluted EPS
$4.21
▲ 56.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-05
Vertex Pharmaceuticals Inc (VRTX) Q4 2023 Earnings Call Transcript
Confident tone
Cystic Fibrosis / vanzacaftor triple (vanza)
Acute pain program VX-548
Pipeline expansion into new disease areas
Revenue
$2.52B*
▲ 9.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-06
Vertex Pharmaceuticals Inc (VRTX) Q3 2023 Earnings Call Transcript
Revenue
$2.48B
▲ 6.4% YoY Diluted EPS
$3.97
▲ 10.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-01
Vertex Pharmaceuticals Inc (VRTX) Q2 2023 Earnings Call Transcript
Revenue
$2.49B
▲ 13.5% YoY Diluted EPS
$3.52
▲ 12.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-01
Vertex Pharmaceuticals Inc (VRTX) Q1 2023 Earnings Call Transcript
Revenue
$2.37B
▲ 13.2% YoY Diluted EPS
$2.69
▼ 9.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-07
Vertex Pharmaceuticals Inc (VRTX) Q4 2022 Earnings Call Transcript
Revenue
$2.30B*
▲ 11.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-27
Vertex Pharmaceuticals Inc (VRTX) Q3 2022 Earnings Call Transcript
Revenue
$2.33B
▲ 17.7% YoY Diluted EPS
$3.59
▲ 9.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Vertex Pharmaceuticals Inc (VRTX) Q2 2022 Earnings Call Transcript
Revenue
$2.20B
▲ 22.5% YoY Diluted EPS
$3.13
▲ 1103.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Vertex Pharmaceuticals Inc (VRTX) Q1 2022 Earnings Call Transcript
Revenue
$2.10B
▲ 21.6% YoY Diluted EPS
$2.96
▲ 18.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-26
Vertex Pharmaceuticals Inc (VRTX) Q4 2021 Earnings Call Transcript
Revenue
$2.07B*
▲ 27.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Vertex Pharmaceuticals Inc (VRTX) Q3 2021 Earnings Call Transcript
Revenue
$1.98B
▲ 29% YoY Diluted EPS
$3.28
▲ 29.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Vertex Pharmaceuticals Inc (VRTX) Q2 2021 Earnings Call Transcript
Revenue
$1.79B
▲ 17.6% YoY Diluted EPS
$0.26
▼ 91.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
Vertex Pharmaceuticals Inc (VRTX) Q1 2021 Earnings Call Transcript
Revenue
$1.72B
▲ 13.8% YoY Diluted EPS
$2.49
▲ 8.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-01
Vertex Pharmaceuticals Inc (VRTX) Q4 2020 Earnings Call Transcript
Revenue
$1.63B
▲ 15.2% YoY Diluted EPS
$2.30
▲ 3.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-29
Vertex Pharmaceuticals Inc (VRTX) Q3 2020 Earnings Call Transcript
Revenue
$1.54B
▲ 62% YoY Diluted EPS
$2.53
▲ 1050% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-30
Vertex Pharmaceuticals Inc (VRTX) Q2 2020 Earnings Call Transcript
Revenue
$1.52B
▲ 62% YoY Diluted EPS
$3.18
▲ 208.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-29
Vertex Pharmaceuticals Inc (VRTX) Q1 2020 Earnings Call Transcript
Revenue
$1.52B
▲ 76.5% YoY Diluted EPS
$2.29
▲ 122.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-30
Vertex Pharmaceuticals Inc (VRTX) Q4 2019 Earnings Call
Revenue
$1.41B
▲ 62.4% YoY Diluted EPS
$2.23
▼ 62.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–32 of 32 earnings calls
Key facts
CIK
875320
CUSIP
92532F100
13F (30d)
41 filings
23 filers
Visit website
Investor relations